2017
DOI: 10.2147/jhc.s103661
|View full text |Cite
|
Sign up to set email alerts
|

Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review

Abstract: According to the current European Association for the Study of Liver guidelines, transarterial chemoembolization (TACE) is the recommended first-line therapy for patients with intermediate-stage (Barcelona Clinic Liver Cancer-B class) hepatocellular carcinoma (HCC). The efficacy of this therapy is supported by robust evidence; however, there is still a lack of standardization in treatment methodology, and TACE protocols are widely variable. Moreover, TACE can be associated with a number of contraindications. D… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

1
54
0

Year Published

2017
2017
2022
2022

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 56 publications
(55 citation statements)
references
References 27 publications
1
54
0
Order By: Relevance
“…Transarterial chemoembolization (TACE) is an approved first‐line therapy for advanced hepatocellular carcinoma (HCC) . However, the response rates to TACE are heterogeneous, and it is not fully understood which patients will most likely benefit from TACE in terms of tumor response .…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Transarterial chemoembolization (TACE) is an approved first‐line therapy for advanced hepatocellular carcinoma (HCC) . However, the response rates to TACE are heterogeneous, and it is not fully understood which patients will most likely benefit from TACE in terms of tumor response .…”
Section: Introductionmentioning
confidence: 99%
“…Transarterial chemoembolization (TACE) is an approved first‐line therapy for advanced hepatocellular carcinoma (HCC) . However, the response rates to TACE are heterogeneous, and it is not fully understood which patients will most likely benefit from TACE in terms of tumor response . Therefore, identification of new practical markers is important to discriminate between patients who will benefit from TACE therapy and those requiring more individualized treatments and rigorous monitoring.…”
Section: Introductionmentioning
confidence: 99%
“…Despite recent advances in treatment methods, such as surgical resection and liver transplantation, curative treatment for advanced tumor stages and patients with metastasis is often not feasible. As a standard therapeutic option for intermediate-stage or non-resectable HCC, transarterial chemoembolization (TACE) has been shown to have benefits (5). According to the Barcelona Clinic Liver Cancer (BCLC) staging system, TACE has been identified as an alternative or combination therapy in patients with early or advanced HCC (6).…”
Section: Introductionmentioning
confidence: 99%
“…Among them, local thermal ablative techniques, including microwave ablation (MWA) and radiofrequency ablation (RFA), have been confirmed as safe and effective for the treatment of patients with HCC in very early stages, based on the Barcelona Clinic Liver Cancer (BCLC) staging system [6]. Meanwhile, as another local minimally invasive therapy, transarterial chemoembolization (TACE) has become one of the most widely used treatment modalities for patients with hypervascular BCLC stage B HCC [7]. All of the aforementioned interventional treatments have distinctive therapeutic characteristics for unresectable HCC, which include high efficiency, minimal invasiveness and relatively short treatment duration [8,9].…”
Section: Introductionmentioning
confidence: 99%